ReviewOncotarget2017

Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer.

Jiantang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.